FDA reduces monitoring time for Amgen’s Imdelltra infusions
The FDA has approved an update to the prescribing information for Amgen’s Imdelltra, cutting the recommended monitoring time for ES-SCLC patients after their first two infusions.
Read the full article on the original site.
Read Full Article